To investigate the therapeutic potential of p53-armed OBP-702 against human CRC cells, human CRC cells with different KRAS/BRAF mutation status were treated with OBP-702 for 72 h, and the viability of the cells was then assessed by XTT assay. The gene discussed is KRAS; the disease is colorectal carcinoma.